

Please refer to the accompanying ICMJE disclosure forms for further details.

Authors' contributions

G.-J.H and M.-S.L designed the letter; M.-S.L wrote the letter; G.-J.H revised the letter.

Acknowledgments

We are grateful to Dr. Hui-Zi Li for his professional support. We are grateful to Dr. Li-Lan Lei (my English teacher), Dr. Ling-Jun Wang, and Dr. Chen-Yang Huang for proofreading and editing.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2021.04.023>.

References

- [1] Ding ZY, Li GX, Chen L, Shu C, Song J, Wang W, et al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. *J Hepatol* 2021;74(6):1295–1302.
- [2] Riley RD, Ensor J, Snell K, Harrell FJ, Martin GP, Reitsma JB, et al. Calculating the sample size required for developing a clinical prediction model. *BMJ* 2020;368:m441.

- [3] Riley RD, Snell KI, Ensor J, Burke DL, Harrell FJ, Moons KG, et al. Minimum sample size for developing a multivariable prediction model: PART II—binary and time-to-event outcomes. *Stat Med* 2019;38(7):1276–1296.
- [4] Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation* 2007;115(7):928–935.
- [5] Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making* 2006;26(6):565–574.
- [6] Burke HB. Overall survival vs disease-specific survival. *JAMA Oncol* 2018;4(4):586.

Meng-Si Luo¹
Guan-Jiang Huang^{2,*}

¹Department of Anesthesiology, Zhongshan Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University of Chinese Medicine, Zhongshan, Guangdong, China

²Department of Otorhinolaryngology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
*Corresponding author. Address: Department of Otorhinolaryngology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou 310009, Zhejiang, China.

E-mail address: hgj719471594@zju.edu.cn (G.-J. Huang)



Liver injury in COVID-19 – The culprit may not be COVID-19!

To the Editor:

We read the study by Ding *et al*¹ with great interest. We congratulate the authors on conducting this large, multicentric study. They have demonstrated that raised levels of aspartate aminotransaminase and direct bilirubin at admission can be used as independent predictors of mortality in patients with coronavirus disease 2019 (COVID-19). They developed a prognostic model with a nomogram that can be used to predict the overall survival probability in patients with COVID-19. Importantly, they have reported that chronic HBV infection is not associated with an increased risk of lethal outcomes in patients with COVID-19. Previous studies have revealed that liver abnormalities occur more frequently in patients with severe COVID-19 and this has been consequential in establishing the association between various liver function abnormalities and their effect on mortality in COVID-19.² This is due to the multiplier effect of multiple organ dysfunction, cytokine storm, drug effects and hypoxic liver injury, rather than the direct cytopathic effect of the SARS-CoV-2. Kulkarni *et al*.³ performed a meta-analysis of 20,874 patients and reported that 3.6% of patients had chronic liver disease (CLD). The odds of developing severe COVID-19 in patients with CLD was 0.81 (95% CI 0.31–2.09; $p = 0.67$) compared to non-CLD patients. COVID-19 patients with elevated liver chemistries had higher risk of mortality (odds ratio [OR] 3.46 [2.42–4.95, $p < 0.001$]) and severe

disease (OR 2.87 [95% CI 2.29–3.6, $p < 0.001$]) compared to patients without elevated liver chemistries. In this study,¹ around 61.8% patients had some abnormal liver chemistry during the course of hospitalization. However, there are some important issues that have not been addressed in the paper.

The study fails to identify underlying CLD as a predictor of worse outcome, possibly due to the small number of patients in the study. Also, the severity of liver disease in terms of various scoring systems has not been correlated with the outcomes. Only 11 individuals had compensated cirrhosis and 3 had decompensated cirrhosis. Standard severity scoring systems like Child-Pugh and model for end-stage liver disease for cirrhosis and Maddrey's discriminant function for alcoholic hepatitis have not been described and correlated with survival.^{4,5}

Although most patients developed some transaminitis during admission, there were several confounding factors that blur the direct association of liver dysfunction attributable to COVID-19. Cai *et al*.⁶ reported use of drugs, systemic inflammation, secondary sepsis, polypharmacy, shock and hypoxia as contributors to liver injury in COVID-19. The presence of hypoxic injury⁷ is also a contributor to liver injury and has not been described in this study. It is evident from the description that the hospitalized patients in this cohort were sick, with most requiring high flow oxygen or invasive ventilation which could have contributed independently to liver injury. Also, the use of various medications during the hospital course should be included in the analysis. The use of hepatotoxic drugs like lopinavir and ritonavir have been shown to be associated with liver injury.⁶ Alcohol abuse or use of Chinese herbal medication before admission should also be

Received 27 January 2021; received in revised form 24 February 2021; accepted 4 March 2021; available online 19 March 2021
<https://doi.org/10.1016/j.jhep.2021.03.010>

determined and adjusted for in multivariate analysis as that can be a potential contributor to liver injury.⁸ The large number of drugs used in clinical trials and variable management of such patients based on evolving evidence also makes comparisons of cohorts difficult.⁹

In conclusion, we believe that Ding *et al.*¹ have meticulously analyzed various liver biochemistry abnormalities during COVID-19. However, the retrospective nature of the cohort, limitations of data, lack of external validation and other confounding factors described merit further investigation and research. It would be premature to attribute deranged liver function to COVID-19 infection alone with the available evidence.

Financial support

The authors received no financial support to produce this manuscript.

Conflict of interest

The authors declare no conflicts of interest.

Please refer to the accompanying ICMJE disclosure forms for further details.

Authors' contributions

AS: writing and critical revision, MP: writing and critical revision, VS: writing and critical revision.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2021.03.010>

References

- [1] Ding Zy, Li Gx, Chen L, Shu C, Song J, Wang W, et al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. *J Hepatol* 2021;74(6):1295–1302.

- [2] Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. *New Engl J Med* 2020;382(18):1708–1720.
- [3] Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. *Aliment Pharmacol Ther* 2020 Aug;52(4):584–599. <https://doi.org/10.1111/apt.15916>.
- [4] Lavarone M, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. *J Hepatol* 2020;73(5):1063–1071.
- [5] Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: preliminary results from an international registry. *J Hepatol* 2020;73(3):705–708.
- [6] Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: abnormal liver function tests. *J Hepatol* 2020;73(3):566–574.
- [7] Ebert EC. Hypoxic liver injury. *Mayo Clinic Proc* 2006;81(9):1232–1236.
- [8] Jing J, Teschke R. Traditional Chinese medicine and herb-induced liver injury: comparison with drug-induced liver injury. *J Clin Transl Hepatol* 2018;6(1):57–68.
- [9] Wong GL, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, et al. Asia-pacific working group for liver derangement during the COVID-19 pandemic. Management of patients with liver derangement during the COVID-19 pandemic: an asia-pacific position statement. *Lancet Gastroenterol Hepatol* 2020;5(8):776–787. [https://doi.org/10.1016/S2468-1253\(20\)30190-4](https://doi.org/10.1016/S2468-1253(20)30190-4). Epub 2020 Jun 23. PMID: 32585136; PMCID: PMC7308747.

Aditya Singh¹

Madhumita Premkumar²

Virendra Singh^{2,*}

¹Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

²Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

*Corresponding author. Address: Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India, 160012; Tel.: 91-172-2756338, fax-91-0172-2744401. E-mail address: virendrasingh100@hotmail.com (V. Singh)



Risk stratification in hospitalized COVID-19 patients

To the Editor:

Ding *et al.* recently published a retrospective analysis of potential predictors for mortality in 2,073 Chinese patients hospitalized with COVID-19.¹ As their main findings, they reported that increased liver parameters as well as liver injury were predictive for 28-day mortality, and proposed a nomogram that estimates the mortality risk of hospitalized patients with COVID-19 disease. However, as the understanding of COVID-19 disease improves, it becomes evident that the disease may present differently in different regions. Liver injury, as well as other gastrointestinal symptoms were associated with worse outcome in some, but not all studies.^{2–7} Therefore, we set out to validate

the main findings in an Austrian cohort of 405 hospitalized patients with COVID-19 disease.

We retrospectively collected demographic and laboratory data as well as in-hospital mortality from all patients with a positive SARS-Cov-2 PCR test hospitalized at either the University Hospital Graz or the State Hospital Graz II between February 28th, 2020 and May 30th, 2020. Due to availability, the nomogram parameters direct bilirubin and troponin I were substituted with total bilirubin and troponin T, respectively. Cox-Regression was used to estimate hazard ratios for 7-, 14-, 21- and 28-day in-hospital mortality; *p* values below 0.05 were considered significant. Monte-Carlo simulation were run to define cut-offs with the highest overall accuracy.

Firstly, we analysed whether elevated liver enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) or liver injury are predictive of 28-day mortality, as proposed in the original article. AST levels above the upper limit of normal were

Keywords: liver function abnormality; mortality; SARS-Cov-2.

Received 11 March 2021; received in revised form 2 April 2021; accepted 12 April 2021; available online 24 April 2021

<https://doi.org/10.1016/j.jhep.2021.04.024>